NCT06781437

Brief Summary

observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,500

participants targeted

Target at P75+ for all trials

Timeline
20mo left

Started Feb 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress72%
Feb 2022Dec 2027

Study Start

First participant enrolled

February 1, 2022

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

December 3, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

January 17, 2025

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

January 17, 2025

Status Verified

October 1, 2024

Enrollment Period

5.9 years

First QC Date

December 3, 2024

Last Update Submit

January 13, 2025

Conditions

Lymphoproliferative Syndrome, AutoimmuneLymphoma

Outcome Measures

Primary Outcomes (1)

  • Incidence and prevalence of lymphomas/lymphoproliferative syndromes referred to the Centre between January 1980 and September 2021

    Incidence and prevalence

    through study completion, an average of 6 years

Secondary Outcomes (12)

  • Overall Survival (OS)

    through study completion, an average of 6 years

  • event free survival (EFS)

    through study completion, an average of 6 years

  • Lymphoma specific survival (LSS)

    through study completion, an average of 6 years

  • Progression Free Survival (PFS)

    through study completion, an average of 6 years

  • Net survival (5 years)

    through study completion, an average of 6 years

  • +7 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021

You may qualify if:

  • Age greater than or equal to 18 years of enrollment
  • Diagnosis of lymphoma or lymphoproliferative syndrome between January 1980 and September 2021
  • Signature of the informed consent form where applicable

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS Azienda Ospedaliero - Universitaria di Bologna

Bologna, Bologna, 40138, Italy

RECRUITING

MeSH Terms

Conditions

Autoimmune Lymphoproliferative SyndromeLymphoma

Condition Hierarchy (Ancestors)

Lymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesAutoimmune DiseasesImmune System DiseasesImmunoproliferative DisordersNeoplasms by Histologic TypeNeoplasms

Study Officials

  • Pier Luigi Zinzani, MD

    IRCCS Azienda Ospedaliero-Universitaria di Bologna

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Pier Luigi Zinzani, MD

CONTACT

+390512143680pierluigi.zinzani@unibo.it

Alessandro Broccoli, MD

CONTACT

+390512143680Alessandro.broccoli@studio.unibo.it

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2024

First Posted

January 17, 2025

Study Start

February 1, 2022

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

January 17, 2025

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations

IT(1)